Pharsight

Lonsurf patents expiration

LONSURF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5744475 TAIHO ONCOLOGY Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
Mar, 2016

(8 years ago)

US9527833 TAIHO ONCOLOGY Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Jun, 2034

(10 years from now)

US10457666 TAIHO ONCOLOGY Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Jun, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6479500 TAIHO ONCOLOGY Agents for alleviating side effects
Mar, 2020

(4 years ago)

US7799783 TAIHO ONCOLOGY Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
Dec, 2026

(2 years from now)

USRE46284 TAIHO ONCOLOGY Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
Sep, 2029

(5 years from now)

US9943537 TAIHO ONCOLOGY Antitumor agent and antitumor effect enhancer
Sep, 2034

(10 years from now)

US10456399 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment
Feb, 2037

(12 years from now)

US10960004 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment
Feb, 2037

(12 years from now)

Lonsurf is owned by Taiho Oncology.

Lonsurf contains Tipiracil Hydrochloride; Trifluridine.

Lonsurf has a total of 9 drug patents out of which 2 drug patents have expired.

Expired drug patents of Lonsurf are:

  • US6479500
  • US5744475

Lonsurf was authorised for market use on 22 September, 2015.

Lonsurf is available in tablet;oral dosage forms.

Lonsurf can be used as treatment of metastatic colorectal cancer alone or with bevacizumab in patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy, treatment of metastatic colorectal cancer with bevacizumab in patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy, treatment of metastatic colorectal cancer alone or with bevacizumab in severely renally impaired patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan therapy, an anti-vegf biologic, and if ras wild-type, anti-egfr therapy, treatment of metastatic gastric or gja in severely renally impaired patients treated with at least two lines of chemotherapy that included a fluoropyrimidine, a platinum, a taxane or irinotecan, and if appropriate, her2/neu-targeted therapy, treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy.

Drug patent challenges can be filed against Lonsurf from 23 September, 2019.

The generics of Lonsurf are possible to be released after 03 February, 2037.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-229) Feb 22, 2026
New Indication(I-794) Feb 22, 2022
New Chemical Entity Exclusivity(NCE) Sep 22, 2020

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

NCE-1 date: 23 September, 2019

Market Authorisation Date: 22 September, 2015

Treatment: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if...

Dosage: TABLET;ORAL

How can I launch a generic of LONSURF before it's drug patent expiration?
More Information on Dosage

LONSURF family patents

Family Patents